About You

For instance, fluctuation in testosterone levels when a child is in distress has been found to be indicative of fathering styles. While the extent of paternal care varies between cultures, higher investment in direct child care has been seen to be correlated with lower average testosterone levels as well as temporary fluctuations. Fatherhood decreases testosterone levels in men, suggesting that the emotions and behaviour tied to paternal care decrease testosterone levels. Physical presence may be required for women who are in relationships for the testosterone–partner interaction, where same-city partnered women have lower testosterone levels than long-distance partnered women. Testosterone levels do not rely on physical presence of a partner; testosterone levels of men engaging in same-city and long-distance relationships are similar.
Despite some heterogeneity, the majority of studies that investigated androgen levels in men with coronary disease, showed that testosterone levels were significantly lower in men with coronary disease than in matched controls. Multiple logistic regression analyses have shown that these differences are not explained by simple differences in coronary risk factor profiles.2 The relationship between male gender and the prevalence of coronary heart disease suggests a role for sex hormones in the aetiology of cardiovascular disease. We discuss the ‘cause' versus ‘effect' controversy, regarding low testosterone levels in men with coronary heart disease, as well as concerns over the use of testosterone replacement therapy in middle aged and elderly men. To the contrary, recent literature has raised concern for increased cardiovascular disease in certain groups of men receiving testosterone therapy. For men who clearly have testosterone deficiency, there is no apparent increased risk of heart attack or stroke or greater chance of developing a new prostate cancer from testosterone replacement therapy. Higher pre-natal testosterone indicated by a low digit ratio as well as adult testosterone levels increased risk of fouls or aggression among male players in a soccer game.
The reflexive testosterone increases in male mice is related to the male's initial level of sexual arousal. Every mammalian species examined demonstrated a marked increase in a male's testosterone level upon encountering a novel female. When testosterone-deprived rats were given medium levels of testosterone, their sexual behaviours (copulation, partner preference, etc.) resumed, but not when given low amounts of the same hormone. In women, correlations may exist between positive orgasm experience and testosterone levels. Common side effects from testosterone medication include acne, swelling, and breast enlargement in males. Decline of testosterone production with age has led to interest in androgen replacement therapy.
Specific proteins include sex hormone-binding globulin (SHBG), which binds testosterone, dihydrotestosterone, estradiol, and other sex steroids. Lipophilic hormones (soluble in lipids but not in water), such as steroid hormones, including testosterone, are transported in water-based blood plasma through specific and non-specific proteins. Test subjects with an artificially enhanced testosterone level generally made better, fairer offers than those who received placebos, thus reducing the risk of a rejection of their offer to a minimum. When controlling for the effects of belief in having received testosterone, women who have received testosterone make fairer offers than women who have not received testosterone. This could explain why some studies find a link between testosterone and pro-social behaviour, if pro-social behaviour is rewarded with social status.
Pubertal effects begin to occur when androgen has been higher than normal adult female levels for months or years. For postnatal effects in both males and females, these are mostly dependent on the levels and duration of circulating free testosterone. The eligibility criteria for this analysis included all placebo-controlled studies that enrolled men (1) with low or low-normal testosterone levels, and (2) who received any testosterone formulation for ≥ 3 months. They concluded that TRT for hypogonadism does not appear to increase PSA or the risk of prostate cancer. No significant adverse CV events were noted.28 Further studies are needed to evaluate the clinical effects of TRT in CHF, but testosterone appears to be a promising therapeutic option for patients with CHF. No definitive statement can be made regarding the effects of testosterone replacement therapy on the levels of either LDL or HDL cholesterol.11 Interpretation of total T concentrations is confounded by variation between individuals, variation in serum SHBG, and variation in androgen sensitivity.6 Furthermore, considerable controversy has arisen regarding the accuracy of currently available commercial testosterone assays, especially those showing T levels at the lower end of the "normal" range.4 Free testosterone level may be a more reliable indicator of androgen status, but more studies are needed to confirm this.
English et al.65 demonstrated similar effects, but in the context of chronic testosterone therapy. Rosano et al.39 investigated the acute effects of intravenous testosterone therapy in a group of men about to perform exercise, treadmill testing. Similar results were found in larger placebo-controlled randomized controlled trials with improvements in exercise capacity, symptom scores, VO2 max, maximal strength, insulin resistance and a reduction in electrocardiographic Q-T dispersion.74, 75, 76 Although these early studies are positive, more evaluation is needed to elucidate the mechanisms of action of testosterone in heart failure and on the long-term effects of supplementation. In a small randomized placebo controlled clinical trial, Pugh et al.73 demonstrated improvements in exercise capacity and in symptom scores after 12 weeks of testosterone therapy in men with heart failure. However, the specific relationship between testosterone and heart failure has not been studied to the same degree as that of testosterone and coronary disease. The prevalence of hypogonadism in men with asymptomatic coronary plaque is similar to the prevalence in men with symptomatic CAD and both groups have lower levels of testosterone than men with normal coronary arteries, supporting a causative role more than a symptomatic consequence (Morris PD, 2001. unpublished data).
Some biological effects of testosterone may result from its aromatization to estradiol and subsequent interaction with the estrogen receptor. Testosterone (T) is the principal male sex hormone, secreted primarily by the testes and transported in the blood by the carrier protein, sex-hormone binding globulin (SHBG). Testosterone replacement therapy (TRT) has been shown to improve myocardial ischemia in men with CAD, improve exercise capacity in patients with CHF, and improve serum glucose levels, HbA1c, and insulin resistance in men with diabetes and prediabetes. Studies have reported a reduced CV risk with higher endogenous T concentration, improvement of known CV risk factors with T therapy, and reduced mortality in T-deficient men who underwent T replacement therapy versus untreated men. In the randomized, placebo-controlled T4DM trial involving men with dysglycemia, testosterone treatment on a background of lifestyle intervention reduced risk of type 2 diabetes mellitus after 2 years.

Profile Info